Shanghai Escugen Biotechnology Co., Ltd

This trial tests whether an experimental drug called ESG206 can safely reduce disease activity in adults with systemic lupus erythematosus (SLE). Participants will receive either ESG206 or a placebo, and researchers will measure how many achieve a meaningful improvement in lupus …

This Phase 2 trial tests an experimental drug called ESG206 in 40 adults with primary Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The drug targets a protein to reduce immune system attacks on the body. Researchers will compare high and low doses against …